Regulatory approval

Published by the Health Canada.

Health Canada approved ipilimumab in combination with nivolumab for the treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.

This is written in the approval document as:

YERVOY, in combination with nivolumab, is indicated for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan.

Citation

Bristol-Myers Squibb Canada. Yervoy (ipilimumab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074279.PDF. Revised December 2023. Accessed June 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)